title: Drug testing with angiogenesis models.
abstract: BACKGROUND
  The possibility to treat cancers and several angiogenesis- dependent diseases with non-toxic, antiangiogenic agents has revolutionized the therapeutic capabilities in the fields of oncology and ophthalmology, whereas therapeutic angiogenesis, governed by angiogenesis stimulators, is about to enter clinical medicine.
  
  
  OBJECTIVE
  To describe and critically evaluate the advantages and limitations of the most important and most frequently used preclinical in vivo angiogenesis assays as well as to appraise the preclinical models that are most widely used for studying antiangiogenic effects in tumors.
  
  
  METHODS
  Up-to-date literature survey.
  
  
  CONCLUSIONS
  Only few angiogenesis and tumor models appear to meet realistic standards fully in terms of biological relevance. Improvement of the biological pertinence and sensitivity of such models would apparently facilitate the translatability of preclinical data into clinical practice.
authors.affiliation: Sahlgrenska University Hospital, Department of Pathology, SE-413 45 Gothenburg, Sweden +46 31 342 19 54 ; +46 31 82 71 94 ; klas.norrby@pathology.gu.se.
authors.forename: Klas
authors.initials: K
authors.lastname: Norrby